225 related articles for article (PubMed ID: 20546451)
1. Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: Longitudinal study using FibroScan.
Wang JH; Changchien CS; Hung CH; Tung WC; Kee KM; Chen CH; Hu TH; Lee CM; Lu SN
J Gastroenterol Hepatol; 2010 May; 25(5):964-9. PubMed ID: 20546451
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study.
Stasi C; Piluso A; Arena U; Salomoni E; Montalto P; Monti M; Boldrini B; Corti G; Marra F; Laffi G; Milani S; Zignego AL
World J Gastroenterol; 2015 Mar; 21(10):3013-9. PubMed ID: 25780300
[TBL] [Abstract][Full Text] [Related]
3. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
[TBL] [Abstract][Full Text] [Related]
4. α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
Tachi Y; Hirai T; Ishizu Y; Honda T; Kuzuya T; Hayashi K; Ishigami M; Goto H
J Gastroenterol Hepatol; 2016 May; 31(5):1001-8. PubMed ID: 27123974
[TBL] [Abstract][Full Text] [Related]
5. FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection.
Yosry A; Fouad R; Alem SA; Elsharkawy A; El-Sayed M; Asem N; Hassan E; Ismail A; Esmat G
Arab J Gastroenterol; 2016 Jun; 17(2):78-83. PubMed ID: 27353055
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of liver stiffness values by means of transient elastography in patients with HCV liver cirrhosis undergoing interferon free treatment.
Sporea I; Lupușoru R; Mare R; Popescu A; Gheorghe L; Iacob S; Șirli R
J Gastrointestin Liver Dis; 2017 Jun; 26(2):145-150. PubMed ID: 28617884
[TBL] [Abstract][Full Text] [Related]
7. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
[TBL] [Abstract][Full Text] [Related]
8. High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C.
Gheorghe L; Iacob S; Grigorescu M; Sporea I; Sirli R; Damian D; Gheorghe C; Iacob R
J Gastrointestin Liver Dis; 2009 Mar; 18(1):51-6. PubMed ID: 19337634
[TBL] [Abstract][Full Text] [Related]
9. Ultrasound elastography correlates treatment response by antiviral therapy in patients with chronic hepatitis C.
Yada N; Sakurai T; Minami T; Arizumi T; Takita M; Inoue T; Hagiwara S; Ueshima K; Nishida N; Kudo M
Oncology; 2014; 87 Suppl 1():118-23. PubMed ID: 25427743
[TBL] [Abstract][Full Text] [Related]
10. Lower liver stiffness in patients with sustained virological response 4 years after treatment for chronic hepatitis C.
Andersen ES; Moessner BK; Christensen PB; Kjær M; Krarup H; Lillevang S; Weis N
Eur J Gastroenterol Hepatol; 2011 Jan; 23(1):41-4. PubMed ID: 21079513
[TBL] [Abstract][Full Text] [Related]
11. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response.
D'Ambrosio R; Aghemo A; Fraquelli M; Rumi MG; Donato MF; Paradis V; Bedossa P; Colombo M
J Hepatol; 2013 Aug; 59(2):251-6. PubMed ID: 23528378
[TBL] [Abstract][Full Text] [Related]
12. Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection.
Aghemo A; Rumi MG; Soffredini R; D'Ambrosio R; Ronchi G; Del Ninno E; Gallus S; Colombo M
Antivir Ther; 2006; 11(6):797-802. PubMed ID: 17310824
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C.
Stasi C; Arena U; Zignego AL; Corti G; Monti M; Triboli E; Pellegrini E; Renzo S; Leoncini L; Marra F; Laffi G; Milani S; Pinzani M
Dig Liver Dis; 2013 Oct; 45(10):840-3. PubMed ID: 23660078
[TBL] [Abstract][Full Text] [Related]
14. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
15. Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection.
Casado JL; Quereda C; Moreno A; Pérez-Elías MJ; Martí-Belda P; Moreno S
J Viral Hepat; 2013 Dec; 20(12):829-37. PubMed ID: 24304452
[TBL] [Abstract][Full Text] [Related]
16. Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response.
Huang CF; Yang JF; Huang JF; Dai CY; Chiu CF; Hou NJ; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML
J Gastroenterol Hepatol; 2010 Apr; 25(4):758-65. PubMed ID: 20492331
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension.
Giannini EG; Basso M; Savarino V; Picciotto A
J Intern Med; 2009 Dec; 266(6):537-46. PubMed ID: 19849774
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
[TBL] [Abstract][Full Text] [Related]
20. Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir.
Bernuth S; Yagmur E; Schuppan D; Sprinzl MF; Zimmermann A; Schad A; Kittner JM; Weyer V; Knapstein J; Schattenberg JM; Wörns MA; Galle PR; Zimmermann T
Dig Liver Dis; 2016 Mar; 48(3):291-7. PubMed ID: 26514736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]